Moderna, Inc. (MRNA) FY2026 Q2 P&L / Income Statement

Moderna, Inc. (MRNA) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (5 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

145,000,000 US dollars

Cost of sales

93,000,000 US dollars

Gross profit (calculated)

52,000,000 US dollars

Operating expenses (calculated)

867,000,000 US dollars

Loss from operations

negative 815,000,000 US dollars

Other income (expense), net (calculated)

48,000,000 US dollars

Loss before income taxes

negative 767,000,000 US dollars

Provision for income taxes

15,000,000 US dollars

Net loss

negative 782,000,000 US dollars

Stand-ready manufacturing revenue

31,000,000 US dollars

Collaboration revenue (Note 5)

15,000,000 US dollars

Grant revenue

2,000,000 US dollars

Licensing and royalty revenue

3,000,000 US dollars

Total other revenue

51,000,000 US dollars

Undisclosed (calculated)

43,000,000 US dollars

Research and development

651,000,000 US dollars

Selling, general and administrative

216,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.